Who Supplies Acetaminophen to India from NEW ZEALAND

Importing finished pharmaceutical formulations containing Acetaminophen into India requires compliance with the Drugs and Cosmetics Act, 1940, and associated rules. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs, including Acetaminophen formulations, be registered and approved before distribution. An Import Registration Certificate and an Import License are essential for legal importation. The registration process involves submitting Form 40 or 41 to CDSCO, along with necessary documentation such as a Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data. The timeline for obtaining these approvals can vary but typically ranges from 6 to 12 months, depending on the completeness of the application and regulatory review processes. For Acetaminophen formulations under HS Code 30049069, adherence to Indian Pharmacopoeia standards is mandatory. Additionally, a No Objection Certificate (NOC) from the Drug Controller General of India (DCGI) may be required, especially if the product is sourced from a Special Economic Zone (SEZ).

Imported Acetaminophen formulations must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian standards. Batch-wise testing is mandatory, with each batch accompanied by a Certificate of Analysis (CoA) confirming conformity to specifications. Stability data, particularly for ICH Zone IV conditions, is required to demonstrate the product's shelf-life under Indian climatic conditions. Upon arrival, customs drug inspectors conduct port inspections to verify the authenticity and quality of the imported goods. If a batch fails to meet the required standards, it may be rejected, destroyed, or re-exported, depending on the severity of the non-compliance. Ensuring that all documentation is accurate and complete is crucial to avoid delays or rejections during the import process.

Between 2024 and 2026, the Indian government has implemented several regulatory updates affecting pharmaceutical imports. The introduction of the Production Linked Incentive (PLI) scheme has incentivized domestic manufacturing, potentially impacting the volume of finished formulation imports, including Acetaminophen products. Additionally, the requirement for import registration and licenses has been emphasized to prevent the sale of unapproved or illegal medicines in the Indian market. Bilateral agreements between India and New Zealand have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined approval processes for pharmaceutical imports. These developments aim to enhance the quality and safety of imported pharmaceutical products while promoting domestic manufacturing capabilities.

India imports finished Acetaminophen formulations to meet the demand for patented and branded products, as well as specific dosage forms not produced domestically. The domestic manufacturing capacity may not fully satisfy the market needs for certain formulations, leading to reliance on imports. The market size for Acetaminophen formulations in India is substantial, driven by their widespread use as analgesics and antipyretics. Imported products often offer advanced formulations, packaging, and quality assurance that appeal to both healthcare providers and consumers.

The import duty structure for Acetaminophen formulations under HS Code 30049069 includes a Basic Customs Duty (BCD) of 10%, an Integrated Goods and Services Tax (IGST) of 12%, and a Social Welfare Surcharge (SWS) of 10% on the BCD. This results in a total landed duty of approximately 23.6% on the assessable value of the imported goods. Anti-dumping duties may apply if the Directorate General of Trade Remedies (DGTR) determines that imports are being dumped at unfairly low prices, potentially harming domestic industries. Exemptions or reduced duty rates can be granted under specific Free Trade Agreements (FTAs) or preferential trade arrangements, subject to compliance with Rules of Origin criteria.

India sources Acetaminophen formulations from New Zealand due to the country's competitive advantages, including adherence to international quality standards, advanced manufacturing technologies, and a reputation for producing high-quality pharmaceutical products. New Zealand's share in India's Acetaminophen import market is modest but significant, offering specialized formulations and dosage forms that may not be readily available from other suppliers. Other major suppliers to India include China, Germany, and the United States, each with their own competitive strengths. New Zealand's unique selling proposition lies in its stringent regulatory compliance, quality assurance, and the ability to provide specialized products tailored to specific market needs.

India imports Acetaminophen formulations from New Zealand due to the country's adherence to international quality standards, advanced manufacturing technologies, and a reputation for producing high-quality pharmaceutical products. New Zealand offers specialized formulations and dosage forms that may not be readily available from other suppliers, catering to specific market needs in India. The importation of these products allows Indian consumers and healthcare providers access to a diverse range of effective and safe Acetaminophen-based medications.

When compared to other major suppliers such as China, Germany, and the United States, New Zealand's competitive advantages include stringent regulatory compliance, high-quality manufacturing, and the ability to provide specialized products tailored to specific market needs. While other countries may offer lower prices or larger volumes, New Zealand's unique selling proposition lies in its commitment to quality, safety, and innovation in pharmaceutical formulations.

Importing Acetaminophen